Progressive Supranuclear Palsy (PSP) is a rare progressive condition that can cause problems with balance, movement, vision, speech, and swallowing. The condition has been linked to changes in certain genes, but these genetic faults are not inherited and the risk to other family members (including the children or siblings) with PSP, is very low.
The only proven risk factor for PSP is age. The condition typically affects people around the age of 60 and is virtually unknown in people under the age of 40. There’s no single test for PSP. Instead, the diagnosis is based on the pattern of the symptoms. The large number of possible symptoms of PSP also makes it difficult to diagnose correctly and can mean it takes a while to get a definitive diagnosis. Apart from this, PSP is often misdiagnosed as Parkinson’s disease, Alzheimer’s disease, corticobasal degeneration, and other neurodegenerative disorders.
The Progressive Supranuclear Palsy market report also covers emerging drugs, current treatment practices, Progressive Supranuclear Palsy market share of the individual therapies, current and forecasted Progressive Supranuclear Palsy Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Progressive Supranuclear Palsy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Progressive Supranuclear Palsy Market Key Facts
- The study titled “The prevalence of progressive supranuclear palsy (Steele–Richards on–Olszewski syndrome) in the UK” by Nath et al. estimated that the prevalence of PSP in the UK was 1.0 per 100,000. The age-adjusted standardized prevalence figure for PSP from this study was observed to be 5.0.
According to a study conducted by Kawashima et al. 2004, in Japan, the prevalence of PSP was 5.82 per 100,000 (men, 9.14; women, 2.75).
The mean age at onset of PSP is approximately 63 years (44–75 years). The median interval between onset and diagnosis is 3 years (range, 0.5–9 years). PSP has a slight male predominance (Eggenberger et al., 2018)
PSP-P is observed in up to one-third of all PSP cases. PSP-PAGF, cortical PSP variants (PSP-CBS, PSP-FTD, PSP-PNFA), and the recently described PSPC are relatively rare and each phenotypic subtype makes up less than five percent of all PSP cases. (Ling et al., 2016)
Key Benefits of Progressive Supranuclear Palsy Market Report
Progressive Supranuclear Palsy market report provides an in-depth analysis of Progressive Supranuclear Palsy Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
The Progressive Supranuclear Palsy market report will help in developing business strategies by understanding the Progressive Supranuclear Palsy Market trends & developments, key players, and future market competition that will shape and drive the Progressive Supranuclear Palsy market in the upcoming years.
The Progressive Supranuclear Palsy market report covers Progressive Supranuclear Palsy’s current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Progressive Supranuclear Palsy market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Progressive Supranuclear Palsy Market
Progressive Supranuclear Palsy Market Size is anticipated to increase during the study period owing to the increasing prevalent population of PSP patients in the 7MM. The launch of upcoming therapies will also boost the market growth.
The Progressive Supranuclear Palsy market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Progressive Supranuclear Palsy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Progressive Supranuclear Palsy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Progressive Supranuclear Palsy Epidemiology
The Progressive Supranuclear Palsy epidemiology section covers insights about the historical and current Progressive Supranuclear Palsy patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Progressive Supranuclear Palsy Epidemiology Segmentation –
Total Prevalent cases
Gender-Specific Prevalent Cases
Diagnosed and Treatable Cases
Type-Specific Prevalent Cases
Age-Specific Prevalent Cases
Progressive Supranuclear Palsy Drugs Uptake and Key Market Players
The Progressive Supranuclear Palsy Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Supranuclear Palsy market or expected to get launched in the market during the study period. The analysis covers Progressive Supranuclear Palsy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Progressive Supranuclear Palsy Companies:
And many others.
Progressive Supranuclear Palsy Therapies covered in the report include:
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Progressive Supranuclear Palsy Competitive Intelligence Analysis
4. Progressive Supranuclear Palsy Market Overview at a Glance
5. Progressive Supranuclear Palsy Disease Background and Overview
6. Progressive Supranuclear Palsy Patient Journey
7. Progressive Supranuclear Palsy Epidemiology and Patient Population
8. Progressive Supranuclear Palsy Treatment Algorithm, Current Treatment, and Medical Practices
9. Progressive Supranuclear Palsy Unmet Needs
10. Key Endpoints of Progressive Supranuclear Palsy Treatment
11. Progressive Supranuclear Palsy Marketed Products
12. Progressive Supranuclear Palsy Emerging Therapies
13. Progressive Supranuclear Palsy Seven Major Market Analysis
14. Attribute Analysis
15. Progressive Supranuclear Palsy Market Outlook (7 major markets)
16. Progressive Supranuclear Palsy Access and Reimbursement Overview
17. KOL Views on the Progressive Supranuclear Palsy Market.
18. Progressive Supranuclear Palsy Market Drivers
19. Progressive Supranuclear Palsy Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market
Latest Reports By DelveInsight
Progressive Supranuclear Palsy (PSP) Epidemiology Forecast
DelveInsight’s Progressive Supranuclear Palsy – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of the Progressive Supranuclear Palsy in the 7MM.
Progressive Supranuclear Palsy Pipeline Insights
Progressive Supranuclear Palsy Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Progressive Supranuclear Palsy market.
Peripheral Vascular Devices Market
DelveInsight’s ‘Peripheral Vascular Devices Market Insights, Competitive Landscape and Market Forecast – 2025’ report delivers an in-depth understanding of Peripheral Vascular Devices Market and the historical and forecasted Peripheral Vascular Devices market trends in the US, EU5 (Germany, Spain, Italy, France and the United Kingdom) and Japan.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States